{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"60.24","value":"0"},{"groupId":"OG001","lowerLimit":"6.76","upperLimit":"93.24","value":"50"},{"groupId":"OG002","lowerLimit":"0.84","upperLimit":"90.57","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"ORR: percentage of participants achieving confirmed partial response rate(PR)or better(stringent complete response\\[sCR\\]+complete response\\[CR\\]+very good partial response\\[VGPR\\]+PR)during study as defined by IMWG uniform response criteria and as determined by investigator.PR:\\>=50%reduction of serum M-protein and\\>=90% reduction in urine M-protein or less than(\\<)200mg/24 hour, or\\>=50%decrease in uninvolved FLC or \\>=50% reduction in plasma cells. At baseline,a \\>=50% decrease in size of soft tissue plasmacytomas was required. Percentages were rounded off to nearest single decimal place. Due to early termination of study no participants were enrolled in Group 2 Arm 4: modakafusp alfa+bortezomib and Group 3 arms, thus they are not presented here. Also, no participants in Group 1 fulfilled criteria for Response-Evaluable Analysis Set, hence are not presented here. Given limited number of participants and low confidence interval as a consequence, those response rate provides limited information.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 80 mg modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with 2 mg pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion was met, whichever occurred first.","id":"OG000","title":"Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 2 mg"},{"description":"Participants received 80 mg modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with 4 mg pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion was met, whichever occurred first.","id":"OG001","title":"Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 4 mg"},{"description":"Participants received 80 mg modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with 20/70 milligrams per meter square (mg/m\\^2) carfilzomib IV, on Day 1, 8 and 15 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion was met, whichever occurred first.","id":"OG002","title":"Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Carfilzomib 20/70 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Response-Evaluable Analysis Set was a subset of SAS including participants with measurable disease at baseline \\& at least 1 post-baseline efficacy evaluation.","reportingStatus":"POSTED","timeFrame":"Up to 16.7 months","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}